The SNMMI Therapy Center of Excellence (Therapy CoE) aims to advance the utilization of targeted radiopharmaceutical therapy through education and collaboration with other organizations and stakeholders. Therapy CoE will be a repository of expertise and knowledge, to advise and augment organizations within SNMMI which are working on issues related to targeted radioisotope therapy.

SNMMI Value Initiative 2.0 – Engagement of Councils and Centers of Excellence
In 2018, SNMMI launched its Value Initiative – a comprehensive strategic plan to advance the crucial role of nuclear medicine and molecular imaging in patient care and science ad discovery. The next step will become SNMMI’s Value Initiative 2.0. As part of Value Initiative 2.0 SNMMI will continue to adjust our organization to the changing health care environment. Value Initiative 2.0 will also engage as many SNMMI members as possible through the work of various committees, working groups, SNMMI councils and centers of excellences and the SNMMI chapters.

As part of this inward focusing effort, councils and centers of excellence will be participating in Domain conference calls and working directly with the chairs from the six (6) domains to address the opportunities and develop strategies to meet them.

As a center of excellence, the Therapy CoE will be involved in every domain; Quality of Practice, Research and Discovery, Workforce Pipeline, Outreach, Advocacy and Organizational Strength and Stability.

Goals and Programs for FY2022
Therapy CoE intends to focus its efforts in the next couple years on initiatives which support and enhance provision of effective radiopharmaceutical therapies for patients, administered by trained practitioners who are part of an integrated health care team. Therapy CoE will continue to address relevant issues and promote RPT through educational and outreach initiatives that include identifying challenges to utilization of RPT, education of providers including nuclear medicine physicians and other providers, referring physicians, and reimbursement and supply issues and quality improvement initiatives.

Additionally, Therapy CoE will promote partnerships for multicenter retrospective and prospective studies.

Specific goals and objectives include:

1. **Theranostics Conference**
   - An annual conference that will comprehensively discuss the clinical aspects and use of RPT in current practice, discuss potential new RPT and clinical trials will be conducted. For 2021, a theranostics conference is to be held in November 10-14, at New Orleans. The aim is to involve multidisciplinary discussion and involvement of medical oncologists and other practitioners, advocacy forums and pharmaceutical stakeholders to better understand and promote utilization and new RPT developments.

2. **Committee on Radiiodine Therapy (CORT)**
   - Presentations at other organizations such as the Thyroid World Congress
   - Conducting a survey to establish a database of facilities performing dosimetry to help determine the prescribed activity for I-131 therapies for patients with differentiated thyroid cancer.

3. **Theranostics Website**
   - The SNMMI Radiopharmaceutical Therapy Central Website was launched in late 2020. It is a dedicated repository for all SNMMI radiopharmaceutical therapy related educational content and resources. The website includes educational content, including on-demand meeting content,
webinars and JNM articles. In addition, guidelines for therapies, including procedure standards and applicable AUCs, along with tools for technologists, patient resources, and the Lu-177 Dosimetry Challenge are all housed there.

4. **Nuclear Medicine Global Initiative**
   The Nuclear Medicine Global Initiative (NMGI) agreed to move forward with Theranostics: an evidence-based NM value as the third topic. The new topic working group is being led by Jean-Luc Urbain, MD, PhD, CPE. The Therapy CoE has two representatives on this group and will be working to provide the SNMMI perspective.

5. **Education**
   The Therapy CoE has and will submit proposals and organize sessions for the SNMMI Mid-Winter and Annual meetings in 2022. Education is high priority. Therapy CoE will continue to engage in the educational activities at SNMMI meetings and will also collaborate with other societies for educational / update sessions. Involvement of the junior faculties and trainees will be emphasized.

6. **Intern**
   The Therapy CoE will support its intern with a substantial project as he completes his term by June 2023.

**Proposed FY22 Budget and Resource Requirements**

1. **Summary of Financial Needs**
   FY21 goals of the Therapy Center will be supported by the attached budget.

2. **Resource Requirements**
   No additional staff, materials, technology, or marketing support is required beyond the usual support provided by SNMMI headquarters.
Therapy Center of Excellence
Background Overview

1. Mission
Therapy CoE is an organizational component within the SNMMI dedicated to all aspects of the development and utilization of Targeted Radioisotope Therapy (TRT) as an alternative to other treatments. Specifically, the new center will bring together a centralized group of all constituents within this area creating a multi-disciplinary interest group whereby industry, big pharma, physicians, scientists, government and regulatory agencies as well as other stakeholders can convene to share ideas, develop education offerings and advance the utilization of radionuclide therapy.

The Therapy Center of Excellence:
(a) Provides a forum for members with similar interests
(b) Provides expertise in TRT
(c) Fosters research and education in TRT
(d) Provides outreach to other professionals and organizations
(e) Nurtures new membership in SNMMI

2. Therapy CoE Board of Directors

Officers
President: Neeta Pandit-Taskar, MD
Vice President: Hossein Jadvar, MD, PhD, FACNM, FSNMMI
Secretary/Treasurer: Thomas Hope, MD
Immediate Past President: Dan Lee, MD

Term
June 2021-June 2023

Directors
*Suzanne E. Lapi, PhD
*Giuseppe Esposito, MD, MBA
Michael S. Hofman, MBBS
AJB (Sandy) McEwan, MD, FSNMMI
Yusuf Menda, MD
David Dick, PhD
Pedram Heidari, MD
Phillip Kuo, MD, PhD
Patrick Colletti, MD, FACNM, FSNMMI
Amir Iravani, MD
Carlos Uribe, PhD, MCCPM

Term
June 2019 – June 2022
June 2019 – June 2022
June 2019 – June 2022
June 2019 – June 2022
June 2019 – June 2022
July 2020 – June 2023
July 2020 – June 2023
June 2021 – June 2024
June 2021 – June 2024
June 2021 – June 2024

Intern (non-voting)
Jaleelat Momodu, MBBS, MPH, FCNP, MMED

Term
June 2021-June 2023
3. Current Status

a. Financial
   As of June 1, 2021, the Therapy CoE has a projected FY21 revenue of $19,299. This includes $5,378 in member dues and $13,852 carryover from FY21. Projected FY21 expenses total $926. Revenue is generated through membership dues, which are $15 annually per member.

b. Membership
   As of July 1, 2021, there were 362 members in the Therapy CoE of which 279 were physicians and scientists, and 52 technologists. The annual membership counts for the past three years are shown below:

<table>
<thead>
<tr>
<th>Year</th>
<th>Membership Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>2020</td>
<td>424</td>
</tr>
<tr>
<td>2019</td>
<td>359</td>
</tr>
<tr>
<td>2018</td>
<td>338</td>
</tr>
<tr>
<td>2017</td>
<td>328</td>
</tr>
</tbody>
</table>

c. Member Benefits
   Member benefits include:
   - Eligibility to vote in the Therapy COE Board of Directors elections
   - Newsletter
   - Sponsored educational symposia related to members’ interests
   - Therapy CoE E-Community
   - A $20.00 discount for Therapy CoE sponsored categorical session.

4. Accomplishments for FY2021
   During the past year the Therapy Center of Excellence was active in educational activities and outreach to the broader medical community. The highlights of the Center’s activities are listed below:

a. Therapy Strategic Planning Task Force
   This past year has been critical for SNMMI as we worked to initiate several new programs and partnerships within the therapy space. As there are multiple internal components within SNMMI working on therapy related activities, it was necessary to bring together the chairs/presidents of these groups to ensure no duplication of effort and collaboration whenever possible. A Radionuclide Therapy Task Force made up of the leadership of the Therapy Center of Excellence, Clinical Trials Network, Outreach Committee and Quality and Evidence Committee continue to meet regularly, led by Richard Wahl, MD and Dan Lee, MD, to meet our therapy strategic plan goals. The task force has met frequently over the past several months to discuss important issues, including Coding & Reimbursement, Dosimetry, Standardization of Clinical Education & Training and Accreditation. This group of expert leaders, along with the Therapy Center of Excellence Board, are working together so that all subject matter experts are up to speed on all therapy related activities being worked on by SNMMI.

   A new therapy-focused web portal for members, researchers, the medical community, and patients launched in December. This portal has been created as a repository for all things therapy, providing direct access to SNMMI’s comprehensive content in one location. The site includes the following content:
   - Educational Activities
   - Guidelines and Appropriate Use Criteria (AUC)
   - Therapy Toolkit for Site Preparation, Regulatory Approval Process, and Implementation
   - Patient Resources
Another initiative for this task force is to oversee the development of radiopharmaceutical therapy registry (RaPTR). A Registry Oversight Committee has been formed that is working with content experts from different committees/councils/centers to develop and implement a pilot phase of this registry. A task force is defining criteria for RPT Centers of Excellence to assist patients in identifying treatment centers.

Following a very successful radiopharmaceutical therapeutics conference held in October 2019, the Quality Committee and the Therapy Center of Excellence are planning to host the second therapeutics conference in November 2021. This meeting will focus on the integration of nuclear medicine in clinical care of patients.

b. 2021 Mid-Winter Meeting and annual meeting Educational Activities
Dedicated CE sessions were organized and presented that included:
1. Prostate cancer theranostics
2. NET nuts and bolts including case discussions
3. Joint session with Pediatric council on updates of theranostics in pediatric patients including novel therapies

c. Multilateral Conference
The first Multilateral Conference on Differentiated Thyroid Cancer was held at Martinique in January 2018, where representatives of SNMMI, the European Association of Nuclear Medicine (EANM), the European Thyroid Association (ETA) and American Thyroid Association (ATA) discussed issues related to the care of patients with thyroid cancer, with particular focus on radioactive iodine (RAI) therapy.

Based on the consensus achieved by the four organizations, a white paper with 9 'Martinique Principles' was developed, "Controversies, Consensus and Collaboration in the Use of I-131 Therapy in Differentiated Thyroid Cancer: A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging and the European Thyroid Association". This consensus document was published in journal Thyroid.

The second multilateral conference was held in March 2019 at Martinique where the participating organizations continued their dialogue and explored areas of further collaboration.

The third Multilateral Consensus Conference was scheduled for March 2020. The participating organizations identified the following controversies in thyroid cancer treatment: peri-operative risk stratification, role of diagnostic radioactive iodine imaging in initial staging and indicators of response to radioactive iodine therapy. However, this meeting was cancelled due to COVID-19 and the expert panel decided to publish a white paper on these controversies. This paper titled, ‘Controversies and Consensus in Thyroid Cancer Care: A Joint Statement from The American Thyroid Association, The European Association Of Nuclear Medicine, The European Thyroid Association, The Society Of Nuclear Medicine And Molecular Imaging On Current Diagnostic And Theranostic Approaches In The Management Of Thyroid Cancer was submitted to journal ‘Thyroid’ for publication earlier this year.

d. Educational Sessions at the 2022 SNMMI Annual Meeting
Sessions on Prostate cancer theranostics and nuts and bolts on practical aspects of clinical RPT have been proposed.
TCoe plans to have 4-5 sessions including categorical and CE session
e. **Saul Hertz Award**  
The 2021 awardee was Eric Krenning, MD whose presentation will be held as a standalone webinar in fall 2021.

f. **Young Investigator Awards**  
These awards are funded by the Education and Research Foundation for Nuclear Medicine and Molecular Imaging.